Please upgrade your browser.
Patients with melanoma or renal cell cancer must have previously received high-dose aldesleukin AND have either progressive or recurrent disease.
Pfizer Inc has announced an innovative patient assistance program to help eligible unemployed Americans and their families who have lost their health insurance maintain access to their Pfizer medicines at no cost. Over 70 Pfizer primary care medicines are available through the program. For more information, call 1-866-706-2400.
Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting. Results from Phase 2 Clinical Trials of Carfilzomib in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Featured in Oral Presentations.
"They said, 'Will you sing?' So I said, 'Yes, because it's for a good cause and we want to raise awareness about kidney cancer.
Physicians should review a patient's CT imaging history and cumulative radiation dose when considering whether to perform another CT exam.
Tens of millions of Americans would lose their current health insurance and could also lose their current doctors, President Obama's reassurances notwithstanding. Since there aren't enough Americans earning more than $250,000 to finance the estimated $1.7 trillion price tag, reform would mean higher taxes for the middle class.
Favorable Response Rate in Patients Who Have Failed Prior Therapy.
Phase III clinical trial results show promise.
These results suggest that a targeted, antiangiogenic, oncolytic adenovirus might be a valuable agent for testing in kidney cancer patients.
If you have renal cell carcinoma and have received no prior systemic therapy (interleukin-2, interferon-alpha, chemotherapy, bevacizumab, mTOR inhibitor, sunitinib, sorafenib or other VEGF TKI), you may qualify for this study. Please see http://www.centerwatch.com/clinical-trials/listings/studylist.aspx?CatID=363.
|Powered by NeonCRM|